()--(2,6-Di-methyl-phen-yl)-1-[(2-meth-oxy-phen-yl)amino]-methanimine oxide methanol monosolvate.

In the title solvate, CHNO·CHO, the dihedral angles between the formamidine backbone and the pendant 2-meth-oxy-phenyl and 2,6-di-methyl-phenyl groups are 14.84 (11) and 81.61 (12)°, respectively.

()--(2,6-Diiso-propyl-phen-yl)-1-[(2-meth-oxyphen-yl)amino]-methanimine oxide.

The mol-ecular structure of the title compound, CHNO reveals non-co-planarity between the central formamidine backbone and each of the outer meth-oxy- and -propyl- substituted benzene rings with dihedral angles of 7.88 (15) and 81.17 (15)°, respectively, indicating significant twists in the mol-ecule.

4'-(2-Meth-oxy-phen-yl)-2,2':6',2''-terpyridine.

In the title compound, CHNO, the N atoms of the pyridine rings exhibit a typical - arrangement: the dihedral angles between the central pyridine ring and the peripheral rings are 22.24 (4) and 2.38 (4)°.

2-Amino-5-oxo-4-(thio-phen-2-yl)-5,6,7,8-tetra-hydro-4-chromene-3-carbo-nitrile.

The crystal structure of the title compound, CHNOS, reveals two symmetrically independent mol-ecules within the asymmetric unit. Each mol-ecule contains a chromenone core attached to a 2-thio-phene ring, cyano, and amino groups. The 2-thio-phene ring of one of the two mol-ecules in the asymmetric unit was found to be disordered over two positions, with the major component having a site occupancy factor of 0.

"If they take it without knowing, they will default…": perceptions of targeted information transfer to promote adherence to intermittent preventive treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy in western Kenya.

Background: Increasing resistance to sulfadoxine-pyrimethamine (SP) threatens the effectiveness of intermittent preventive treatment (IPTp) to prevent malaria in pregnancy. Dihydroartemisinin-piperaquine (DP) is the most promising candidate to emerge from clinical trials, but requires a multi-day regimen. Despite being a single-dose regimen, coverage of IPTp-SP remains low, fuelling concerns about adherence to multi-day drug options.